Core growth accelerates as bioprocessing orders sustain recovery
- Q3 2026 core growth excluding respiratory reached 5.5 percent.
- Bioprocessing equipment and consumable orders grew in the mid-teens.
- New CEO Julie Sawyer Montgomery launched a connected commercial strategy.
- The company announced an AI-powered autonomous lab and a computing partnership with NVIDIA.
- The recently acquired Masimo business received FDA clearance for its atrial fibrillation platform.
A choppy path to recovery
Danaher is navigating a complex but improving recovery. The third quarter of 2026 provided strong validation, with core growth excluding respiratory reaching 5.5 percent. The company is leaning into a new era under CEO Julie Sawyer Montgomery, prioritizing a connected commercial strategy and heavy investments in artificial intelligence to capture more spending from its customers.
The bull case centers on the durability of the bioprocessing recovery and the potential of new technology. Bioprocessing orders grew in the mid-teens during the third quarter, easing fears from earlier shipment delays. Furthermore, a new autonomous lab and a partnership with NVIDIA give Danaher a first-mover advantage in AI-enabled research automation, which could accelerate market share gains.
The bear case focuses on persistent headwinds. Respiratory testing remains a drag on the Diagnostics segment, with 2026 revenue planned to fall to $1.5 billion. Management also noted that financial benefits from bioprocessing reshoring are pushed out to 2028 or later. This means near-term upside relies heavily on traditional pharmaceutical markets continuing their gradual recovery.
Instruments create repeat sales
Danaher sells instruments, then earns repeat revenue from the supplies, tests, software, and services those instruments require. A laboratory or hospital might buy a machine once, but it continues buying consumables for years if that machine becomes part of daily operations.
The company operates under the Danaher Business System, known as DBS. This internal culture focuses on continuous improvement for quality, speed, cost, and customer service. The goal is simple: acquire or build strong science businesses, then run them better.
Under new leadership, Danaher is shifting toward a connected strategy. Instead of operating companies selling independently, the firm aims to cross-sell integrated solutions across its portfolio. This includes leveraging artificial intelligence to speed up discovery workflows for customers.
Acquisitions remain central to the strategy. While mergers and acquisitions are the preferred use of capital, Danaher will buy back shares when the return profile is attractive, as shown by a $2 billion repurchase earlier in the year.
Tools behind labs and tests
Bioprocessing systems
Danaher sells filtration, manufacturing, and workflow tools used to make biologic drugs. Equipment sales returned to revenue growth in mid-2026.
Bioprocessing consumables
These are repeat-use supplies tied to drug production. Order volumes are accelerating despite isolated shipment delays earlier in the year.
Life Sciences instruments
Products include mass spectrometry, microscopy, and digital pathology. The portfolio now integrates AI-powered autonomous lab workflows.
Genomics and gene editing consumables
Danaher sells products used in gene reading, writing, and editing. Subsidiaries like IDT and Abcam provide critical supplies for this research.
Molecular diagnostics
Cepheid's GeneXpert system runs tests for respiratory illness and other needs. Respiratory testing remains a significant financial headwind.
Clinical diagnostics & monitoring
Beckman Coulter analyzers and the newly acquired Masimo patient monitoring tools help hospitals diagnose disease and track patient health.
Three pieces, one swing factor
Segment mix uses Danaher's Q1 2026 sales by segment: Biotechnology $1.797 billion, Life Sciences $1.737 billion, and Diagnostics $2.417 billion. The mix remains stable, but Biotechnology and Life Sciences are the primary focus for recovery.
What could go wrong
Lumpy bioprocessing demand
High impact · Medium oddsBioprocessing is recovering, but customer behavior remains unpredictable. While order growth is strong, any return to delayed shipments or paused capital spending would threaten revenue targets.
Respiratory testing remains soft
Medium impact · Medium oddsDiagnostics core sales continue to face pressure from respiratory testing. A mild winter season for respiratory illness will severely limit the overall segment performance.
Connected strategy execution
Medium impact · Low oddsThe new commercial strategy aims to integrate sales across independent operating companies. This could disrupt the accountability and agility that made these individual businesses successful.
Trade and conflict shocks
Medium impact · Low oddsDanaher operates a global supply chain. The company has highlighted that military conflicts could disrupt logistics or raise costs, causing delays in product delivery.
In one breath
What does Danaher actually do?
Danaher sells tools and supplies used in life science research, biologic drug manufacturing, and clinical diagnostics. Its products help scientists study disease, help drug companies make biologic medicines, and help hospitals run tests.
Why does bioprocessing matter so much for Danaher stock?
Bioprocessing is tied to the equipment and consumables used to make biologic drugs. Orders are currently growing in the mid-teens, which signals that customers are spending again after a long pause.
How is the Diagnostics segment performing?
Clinical diagnostics remain solid, and the recently acquired Masimo business is delivering steady growth. However, weak demand for respiratory testing continues to act as a drag on total segment growth.
How is Danaher using artificial intelligence?
The company recently launched an AI-powered autonomous lab and announced a computing partnership with NVIDIA. These investments aim to automate and speed up discovery workflows for scientific customers.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- October 25, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Diagnostics & Research companies
Companies near Danaher Corporation in Finn's Diagnostics & Research industry ranking.

